VICL News and Press, Vical Incorporated From 06/03/19

DelMar Pharmaceuticals (NASDAQ: DMPI )  -41%  on equity offering . More news on: DelMar Pharmaceuticals, Inc., Vascular Biogenics Ltd., Centene Corporation, Stocks on the move, Read more ...

Combined Company Well-Capitalized with Approximately $35 Million in Cash and up to $25 Million in Near-Term R&D Funding Pivotal Phase 3 Clinical Trials for Brickell’s Lead Product Candidate, Sofpironium Bromide, in Patients with Axillary Hyperhidrosis Planned for Q4 2019 ...

Vical ( VICL ) is a failed bio pharma company that has initially looked like an interesting opportunity to invest, however a bit more research has shown that the margin of safety might be not enough (22% to net cash and 5% in case of a liquidation). Share count is largely diluted by the pre-fu...

Net nets are hard to find. A net net is where the stock trades below working capital minus long-term liabilities. Usually they have all kinds of warts and are bleeding heavily. Vical (VICL) is the best example I have seen in some time as it is trading at less than half of cash and the bleed ra...

Vical (NASDAQ: VICL ): Q4 GAAP EPS of -$0.17. More news on: Vical Incorporated, Earnings news and commentary, Healthcare stocks news, , Read more ...

SAN DIEGO, Feb. 19, 2019 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced that it has decided to discontinue the Phase 2 clinical trial of VL‑2397 that was initiated in the first quarter of 2018. The decision was based on the Company’s decision to conserve ...

NEW YORK, Nov. 01, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Interface, Inc. (NASDAQ:TILE), USA Truck, Inc. (NASDAQ:USAK), Weingart...

Vical ( VICL ) Q3 results: Revenues: $0.05M (-98.4%); Net Loss: ($1.5M) (+51.6%); Loss Per Share: ($0.07) (+74.1%). More news on: Vical Incorporated, Healthcare stocks news, Earnings news and commentary, , Read more ...

Vical (NASDAQ: VICL ): Q3 GAAP EPS of -$0.07 beats by $0.15 . More news on: Vical Incorporated, Earnings news and commentary, Healthcare stocks news, , Read more ...

SAN DIEGO, Oct. 29, 2018 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today reported financial results for the three months ended September 30, 2018. Net loss for the third quarter of 2018 was $1.5 million, or $0.07 per share, compared with a net loss of $3.1 million, or $0.27 per s...